`
`
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`
`)
`) MDL No. 22-MD-3038 (CFC)
`) ANDA CASE
`)
`)
`)
`
`
`
`)
`)
`) C.A. No. 22-294 (CFC)
`) CONSOLIDATED
`ANDA CASE
`
`) )
`
`) ) )
`
`
`)
`)
`)
`
`
`) )
`
`
`IN RE: OZEMPIC (SEMAGLUTIDE)
`PATENT LITIGATION
`
`
`NOVO NORDISK INC. and
`NOVO NORDISK A/S,
`
`Plaintiffs,
`
`
`v.
`
`
`RIO BIOPHARMACEUTICALS INC.,
`et al.,
`
`Defendants.
`
`
`NOVO NORDISK INC. and
`NOVO NORDISK A/S,
`
`Plaintiffs,
`
`
`
`v.
`
`
`)
`) C.A. No. 22-1040 (CFC)
`) ANDA CASE
`)
`
`MYLAN PHARMACEUTICALS INC., )
`
`
`) )
`
`
`)
`
`Defendant.
`
`
`JOINT STIPULATION AND ORDER
`AMENDING SCHEDULING ORDER
`
`WHEREAS, Plaintiffs Novo Nordisk Inc. and Novo Nordisk A/S and
`
`Defendants Alvogen, Inc., Dr. Reddy’s Laboratories, Ltd., Dr. Reddy’s
`
`Laboratories, Inc., Mylan Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd.,
`
`1
`
`Novo Nordisk Exhibit 2009
`Dr. Reddy's Laboratories v. Novo Nordisk A/S
`IPR2024-00009
`Page 00001
`
`
`
`Case 1:22-md-03038-CFC Document 268 Filed 12/01/23 Page 2 of 7 PageID #: 5380
`
`Sun Pharmaceutical Industries Inc., Rio Pharmaceuticals, Inc., EMS SA, Zydus
`
`Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences
`
`Limited (collectively, the "Defendants") have agreed, subject to the approval of the
`
`Court, to extend certain deadlines set forth in the Scheduling Order (D .I. 22, as
`
`amended by D.I. 214).
`
`IT IS HEREBY STIPULATED AND AGREED, by the undersigned
`
`counsel, subject to the approval of the Court, that the following dates set forth in the
`
`Scheduling Order shall be amended consistent with the table set forth below:
`
`Event
`
`Amended Deadline
`
`Current
`Deadline
`December 1, December 15, 2023
`2023
`
`Close of Fact
`Discovery
`(limited to the
`completion of all
`previously-
`noticed fact
`depositions)
`Final Deadline
`to Supplement
`the Preliminary
`Disclosure of
`Asserted Claims
`and Preliminary
`Disclosure of
`Prior Art, ,r 11.
`28 days after Within 4 days after the final deadline to
`Defendants
`serve on
`Court issues a Supplement the Preliminary Disclosure of
`Plaintiffs a
`Asserted Claims and Preliminary Disclosure of
`Claim
`"Final Election Construction
`0rior Art, or by agreement of the parties.
`of Asserted Prior Order
`Art" relating to
`the '953 and
`
`December 1,
`2023
`
`~or the '953 and '383 patents, within one week
`after the Court's ruling on supplemental Markman
`or agreement by the parties, whichever is earlier.
`
`No further supplementation shall be permitted
`with respect to the '343, '122 and '462 patents
`absent an order of the Court.
`
`2
`
`Novo Nordisk Exhibit 2009
`Dr. Reddy's Laboratories v. Novo Nordisk A/S
`IPR2024-00009
`Page 00002
`
`
`
`Case 1:22-md-03038-CFC Document 268 Filed 12/01/23 Page 3 of 7 PageID #: 5381
`
`Event
`
`Current
`Deadline
`
`Amended Deadline
`
`'3 83 patents, ,r
`23.
`Plaintiffs serve
`14 days after Within 4 days after the service of Final Election of
`on Defendants a
`service of the Asserted Prior Art, or by agreement of the parties.
`"Final Election
`Final Election
`of Asserted
`of Asserted
`Claims" relating Prior Art
`to the '953 and
`'3 83 patents,
`123.
`Final Deadline
`to Supplement
`Infringement
`Contentions and
`Invalidity
`Contentions, ,r
`11.
`Final Deadline
`to Supplement
`N oninfringement
`Contentions and
`Responses to
`Invalidity
`Contentions, ,r
`11.
`Opening Expert
`Reports
`(including
`Plaintiffs'
`Secondary
`Indicia
`Opinions), il24.
`Rebuttal Expert March 1, 2024 April 5, 2024
`Reports
`(including
`Defendants'
`Secondary
`
`December 15, ~ebruary 9, 2024 for the '343, '122, and '462
`patents.
`2023
`
`December 1,
`2023
`
`January 12, 2024 for the ' 343, '122, and '462
`patents.
`
`~ebruary 1, 2024 for the '953 and ' 383 patents.
`
`~ebruary 22, 2024 for the '953 and ' 383 patents.
`
`January 19,
`2024
`
`March 1, 2024
`
`3
`
`Novo Nordisk Exhibit 2009
`Dr. Reddy's Laboratories v. Novo Nordisk A/S
`IPR2024-00009
`Page 00003
`
`
`
`Case 1:22-md-03038-CFC Document 268 Filed 12/01/23 Page 4 of 7 PageID #: 5382
`
`Event
`
`Current
`Deadline
`
`Amended Deadline
`
`Indicia
`Opinions), if 24.
`Reply Expert
`Reports, ,r 24.
`Close of Expert May 24, 2024
`Discovery, 124.
`
`April 5, 2024 May 3, 2024
`
`June 7, 2024
`
`No other deadlines set forth in the Scheduling Order are altered by way of this
`stipulation.
`Counsel certify that a copy of this stipulation has been sent to their respective
`clients pursuant to D. Del. LR 16.4.
`
`4
`
`Novo Nordisk Exhibit 2009
`Dr. Reddy's Laboratories v. Novo Nordisk A/S
`IPR2024-00009
`Page 00004
`
`
`
`Case 1:22-md-03038-CFC Document 268 Filed 12/01/23 Page 5 of 7 PageID #: 5383
`
`
`
`
`
`MORRIS, NICHOLS, ARSHT &
`TUNNELL LLP
`
`/s/ Travis J. Murray
`
`Jack B. Blumenfeld (#1014)
`Brian P. Egan (#6227)
`Travis J. Murray (#6882)
`1201 North Market Street
`P.O. Box 1347
`Wilmington, DE 19899
`(302) 658-9200
`jblumenfeld@morrisnichols.com
`began@morrisnichols.com
`tmurray@morrisnichols.com
`
`Attorneys for Plaintiffs
`
`YOUNG CONAWAY STARGATT &
`TAYLOR, LLP
`
`/s/ Pilar G. Kraman
`Pilar G. Kraman (#5199)
`Rodney Square
`1000 North King Street
`Wilmington, DE 19801
`(302) 571-6600
`pkraman@ycst.com
`
`
`Attorneys for Defendants Zydus
`Worldwide DMCC, Zydus
`Pharmaceuticals (USA) Inc., and
`Zydus Lifesciences Limited
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`HEYMAN ENERIO GATTUSO &
`HIRZEL LLP
`
`/s/ Dominick T. Gattuso
`Dominick T. Gattuso (#3630)
`300 Delaware Avenue, Suite 200
`Wilmington, DE 19801
`(302) 472-7300
`dgattuso@hegh.law
`
`Attorneys for Defendants Dr.
`Reddy’s Laboratories, Ltd. and Dr.
`Reddy’s Laboratories, Inc.
`
`
`
`
`RICHARDS, LAYTON & FINGER, P.A.
`
`
`/s/ Kelly E. Farnan
`Kelly E. Farnan (#4395)
`Sara M. Metzler (#6509)
`One Rodney Square
`920 North King Street
`Wilmington, DE 19801
`302-651-7705
`farnan@rlf.com
`metzler@rlf.com
`
`Attorneys for Defendants Sun
`Pharmaceutical Industries Ltd. and
`Sun Pharmaceutical Industries Inc.
`
`
`
`
`
`
`
`
`
`
`
`
`
`5
`
`Novo Nordisk Exhibit 2009
`Dr. Reddy's Laboratories v. Novo Nordisk A/S
`IPR2024-00009
`Page 00005
`
`
`
`Case 1:22-md-03038-CFC Document 268 Filed 12/01/23 Page 6 of 7 PageID #: 5384
`
`
`
`MORRIS JAMES LLP
`
`/s/ Kenneth L. Dorsney___________
`Kenneth L. Dorsney (#3726)
`Cortlan S. Hitch (#6720)
`500 Delaware Avenue, Suite 1500
`Wilmington, DE 19801
`(302) 888-6800
`kdorsney@morrisjames.com
`chitch@morrisjames.com
`
`
`
`Attorneys for Defendants Rio
`Pharmaceuticals, Inc. and EMS S/A
`
`
`
`
`
`SHAW KELLER LLP
`
`
`/s/ Nathan R. Hoeschen
`Karen E. Keller (No. 4489)
`Nathan R. Hoeschen (No. 6232)
`Emily S. DiBenedetto (No. 6779)
`I.M. Pei Building
`1105 North Market Street,
`12th Floor
`Wilmington, DE 19801
`(302) 298-0700
`kkeller@shawkeller.com
`nhoeschen@shawkeller.com
`edibenedetto@shawkeller.com
`
`Attorneys for Defendant Alvogen,
`Inc.
`
`STAMOULIS & WEINBLATT LLC
`
`
`/s/ Stamatios Stamoulis
`Stamatios Stamoulis (#4606)
`Richard C. Weinblatt (#5080)
`800 N. West Street, Third Floor
`Wilmington, DE 19801
`(302) 999-1540
`stamoulis@swdelaw.com
`weinblatt@swdelaw.com
`
`Attorney for Defendant Mylan
`Pharmaceuticals, Inc.
`
`
`
`
`
`Dated: November 30, 2023
`
`
`
`
`
`
`
`6
`
`Novo Nordisk Exhibit 2009
`Dr. Reddy's Laboratories v. Novo Nordisk A/S
`IPR2024-00009
`Page 00006
`
`
`
`Case 1:22-md-03038-CFC Document 268 Filed 12/01/23 Page 7 of 7 PageID #: 5385
`
`
`
`S O O R D E R E D , this ___________ day of December, 2023.
`
`
`______________________________________________
`CHIEF, UNITED STATES DISTRICT COURT JUDGE
`DISTRICT OF DELAWARE
`
`
`
`7
`
`1st
`
`/s/ Colm F. Connolly
`
`Novo Nordisk Exhibit 2009
`Dr. Reddy's Laboratories v. Novo Nordisk A/S
`IPR2024-00009
`Page 00007
`
`